With these changes and more to come, the company can do some real soul searching.
Dr. Kellmeyer definitely has the trial experience (that Missling lacked) with bio-statistical input from Dr. Jun and clinical input from Dr, Liedtke to properly design and execute appropriate trial that can pass muster with the FDA/EMA if results are good. She lacks the finance experience. If she stays on as CEO, Anavex will likely need to get rid of Sandra Boenisch and hire a full time higher level CFO. There is not enough cash to exist 3 years if more trials are to start. Diluition is fine if progress is being made.
We have seen only the clinical data that Missling wanted us to see and as I've posted in multiple times, it is lacking for any further action by the EMA or FDA.
She, Dr. Jun and Dr. Liedkte have seen all the data, warts and all. A273 may just not be that effective for AD. When they take a step back to look at the data from a regulatory viewpoint is there enough to spend 80 million to do a proper P3 (800+ patients, 72 weeks, screen out S1R Q2P variants, place Col24A in the hierarchy). Or is the data so weak when looked at objectively that the A273 program should just be shuttered? Is a pivot to A371 for schizo a better move? Doing both will require a capital raise sooner.
The language of the PR - request for resignation, implies more than just being fired for poor results. He controlled 3/6 votes (himself, Thomas, Donhauser) on the BOD so either one turned, or in matters of TGD, he can't vote and he was fired 3-2 by the non-buddy BOD members. Will be interesting to see what comes out in the next couple weeks and at the CC (whenever that will be).
Market Data 
Markets 
